Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 20/20 | 1.00 |
| ▸ | TRPV4 | Q9HBA0 | 9/20 | 0.82 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799281 | 0.91 | TRPA1 (0.84) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1802300 | 0.90 | TRPA1 (1.00) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1800120 | 0.90 | TRPA1 (1.00) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1803050 | 0.90 | TRPA1 (0.81) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1801559 | 0.89 | TRPA1 (0.86) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1800702 | 0.89 | TRPA1 (0.80) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1801729 | 0.89 | TRPA1 (1.00) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1803001 | 0.88 | TRPA1 (0.82) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1799394 | 0.88 | TRPA1 (0.81) | TRPA1TRPV4TRPV3 | |
| SCHEMBL1799951 | 0.87 | TRPA1 (0.84) | TRPA1TRPV4TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | claimed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | claimed |
| US-20160158236-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160158236-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9186360-B2 | Treatment of respiratory disorders using TRPA1 antagonists | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9186360-B2 | Treatment of respiratory disorders using TRPA1 antagonists | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-11-17 | — | — | US | disclosed |
| US-20140364445-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364445-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140148423-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-05-29 | — | — | US | disclosed |
| US-20140148423-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-05-29 | — | — | US | disclosed |
| WO-2013084153-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012172475-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-12-20 | — | — | WO | disclosed |
| US-20120316136-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| WO-2010004390-A1 | QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364445-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT | TRPA1, TRPV1, TRPV5 | TRPA1 1/4885TRPV4 9/4885TRPV3 6/4885 |
| US-20120316136-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885TRPV4 5/4885TRPV3 4/4885 |
| US-20160158236-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885TRPV4 5/4885TRPV3 4/4885 |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPC3 | TRPA1 1/4885TRPV4 6/4885TRPV3 4/4885 |
| US-20140148423-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885TRPV4 5/4885TRPV3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.